<PAGE>
+--------+
| FORM 3 | U.S. SECURITIES AND EXCHANGE COMMISSION
+--------+ WASHINGTON, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
(Print or Type Responses)
- --------------------------------------------------------------------------------
1. Name and Address of Reporting Person*
E.I. du Pont de Nemours and Company
----------------------------------------------------------------------------
(Last) (First) (Middle)
1007 Market Street
----------------------------------------------------------------------------
(Street)
Wilmington, Delaware 19898
----------------------------------------------------------------------------
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year) 10/05/99
--------------
3. IRS Identification Number of Reporting Person if an Entity
(Voluntary)
--------------
4. Issuer Name and Ticker or Trading Symbol CombiChem, Inc.
(Symbol NASDAQ:CCHM)
-----------------------------------
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
[ ] Director [ ] Officer [ ] 10% Owner [ ] Other
(give title below) (specify below)
(See attached)
<PAGE>
6. If Amendment, Date of Original (Month/Day/Year)
----------------------------
7. Individual or Joint Group Filing (Check Applicable Line)
Form Filed by One Reporting Person
----
X Form filed by More than One Reporting Person
----
TABLE I--NON-DERIVATIVE SECURITIES BENEFICIALLY OWNED
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------
1. Title 2. Amount of 3. Ownership Form: 4. Nature of
of Securities Bene- Direct (D) or Indirect Bene-
Security ficially Owned Indirect (I) ficial Ownership
(Instr. 4) (Instr. 4) (Instr. 5) (Instr. 5)
- --------------------------------------------------------------------------------
<S> <C> <C> <C>
Common Stock,
par value 7,662,280
$0.001 per share (see attached) (I) (see attached)
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
*If the form is filed by more than one reporting person, see
Instruction 5(b)(v).
2
<PAGE>
FORM 3 (continued)
TABLE II--DERIVATIVE SECURITIES BENEFICIALLY OWNED
(e.g., puts, calls, warrants, options, convertible securities)
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------------
1. Title of Derivative 2. Date Exer- 3. Title and Amount of Securities 4. Conversion 5. Ownership 6. Nature of In-
Security (Instr. 4) cisable and Underlying Derivative Security or Form of direct Bene-
Expiration (Instr. 4) Exercise Derivative ficial
Date Price Security: Ownership
(Month/Day/ of Direct (D) (Instr. 5)
Year) Derivative or In-
---------------------------------------------------- Security direct (I)
Date Expira- Amount or (Instr. 5)
Exer- tion Title Number of
cisable Date Shares
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C>
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
- --------------------------------------------------------------------------------
Explanation of Responses:
This Initial Statement of Beneficial Ownership on Form 3 (this "Form 3")
is being filed by E.I. du Pont de Nemours and Company, a Delaware corporation
("Parent"),and DuPont Pharma, Inc., a Delaware corporation and wholly owned
subsidiary of Parent ("Purchaser"), and DPC Newco, Inc., a Delaware corporation
and wholly owned subsidiary of Purchaser ("Merger Sub"). On October 5, 1999,
Parent, Merger Sub and CombiChem, Inc. a Delaware corporation ("CombiChem")
entered into an Agreement and Plan of Merger (the "Merger Agreement") providing
for, among other things, the merger of Merger Sub with and into CombiChem.
Simultaneously with the execution and delivery of the Merger Agreement, Parent
and Merger Sub entered into a Shareholders Agreement, dated as of October 5,
1999 (the "Shareholders Agreement"), with certain major shareholders of
CombiChem (the "Major Stockholders") who, as of September 27, 1999 owned
4,549,591 shares of CombiChem Common Stock and options and warrants exercisable
for 428,258 shares of CombiChem Common Stock, in the aggregate. Under the
Shareholders Agreement, the Major Stockholders have agreed, subject to the terms
thereof, to tender all of their shares of CombiChem Common Stock to Merger Sub
pursuant to the tender offer described in the Merger Agreement, and to vote
their shares in favor of the merger described in the Merger Agreement. The Major
Stockholders have also granted Merger Sub a proxy to vote their shares,
representing approximately 33.7% of the issued and outstanding shares of
CombiChem Common Stock as of September 27, 1999, in favor of the merger.
Simultaneously with the execution and delivery of the Merger Agreement, Parent
and Merger Sub also entered into a Stock Option Agreement (the "Option
Agreement") pursuant to which CombiChem granted to Parent an option to purchase
2,684,431 shares of CombiChem Common Stock, subject to the terms thereof. If
this option were to be exercised and these shares were issued to Parent and
outstanding, such shares would, together with the shares subject to the
Shareholders Agreement, represent approximately 44.1% of the issued and
outstanding shares of CombiChem Common Stock as of September 27, 1999. Parent
assigned all of its rights under the Merger Agreement, the Shareholders
Agreement and the Option Agreement to Purchaser and Purchaser agreed to assume
all of the obligations of Parent thereunder.
3
<PAGE>
The foregoing summary of the Merger Agreement, the Shareholders Agreement
and the Option Agreement is qualified in its entirety by reference to such
agreements, which have been filed as exhibits to the Schedule 13D and the
Schedule 14D-1 filed with respect to CombiChem on the date hereof and October
12, 1999 respectively.
**Intentional misstatements or omissions of facts constitute Federal Criminal
Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
/s/ John P. Jessup 10/15/99
------------------------------- --------
**Signature of Reporting Person Date
Vice President and Controller
on behalf of E.I. du Pont de Nemours
and Company
4
<PAGE>
Joint Filer Information
Names: DuPont Pharma, Inc.
DPC Newco, Inc.
Address: c/o E.I. du Pont de Nemours and Company
1007 Market Street
Wilmington, Delaware 19898
Designated Filer: E.I. du Pont de Nemours and Company
Issuer &
Ticker Symbol: CombiChem, Inc. (CCHM)
Date of Event
Requiring Statement: 10/05/99
Signatures: DuPont Pharma, Inc.
/s/ A. Lloyd Adams 10/15/99
------------------------------- ------
A. Lloyd Adams Date
Vice President and
Assistant Treasurer
DPC Newco, Inc.
/s/ Steven J. Capolarello 10/15/99
------------------------------- ------
Steven J. Capolarello Date
Vice President and Treasurer
5
